BioSignal Discovery

BioSignal Discovery is a preclinical-stage biotechnology company specializing in the development of small molecule inhibitors targeting Regulator of G-protein Signaling (RGS) proteins. A spin-out from the University of Michigan, the company utilizes a high-throughput screening platform to identify compounds that modulate G-protein coupled receptor (GPCR) signaling by inhibiting the RGS proteins that normally terminate these signals. Their lead research programs focus on RGS4 for the treatment of central nervous system disorders, such as neuropathic pain and Parkinson's disease, and RGS2 for cardiovascular indications like hypertension. Additionally, the company has explored RGS inhibitors as potential therapies for uveal melanoma. While the company's active operations have diminished, its foundational work remains a significant contribution to the field of GPCR pharmacology.